ImmunoMod, LLC, founded in March 2006, is a privately-held biotechnology company developing and commercializing pharmaceuticals for the treatment, prevention and cure of diabetes and related auto-immune disorders. Our preliminary focus is preventing the onset of Type 1 Diabetes by protecting beta cell function in early-stage diabetic youth. We currently have a portfolio of pre-clinical and clinical candidates, one of which will begin preliminary Phase II trials in Fall 2006 after promising results in Phase I trials.
Immunomod
Menu:
Our Focus
Products
Company Statement
ImmunoMod develops novel therapeutics to alleviate human suffering caused by diabetes and related auto-immune disorders.
